Physician profile
Nancy T Vu
NPI 1821059957
$21,175.55
in general payments reported to CMS, 2019-2025
50 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,181 · 2020: $1,871 · 2021: $2,962 · 2022: $4,139 · 2023: $5,088 · 2024: $3,935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,927 · Education: $95.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,927.14 |
| Education | $95.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,815.92 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Biogen, INC. | $1,528.60 | 2019-2024 | Vumerity, Tysabri, Leqembi |
| Neurocrine Biosciences, INC. | $1,486.25 | 2019-2024 | Ingrezza, Ongentys |
| Novartis Pharmaceuticals Corporation | $1,464.36 | 2019-2024 | |
| Emd Serono, INC. | $1,405.89 | 2019-2024 | Mavenclad, Mavenclad |
| Ucb, INC. | $1,318.61 | 2019-2024 | Briviact, Nayzilam |
| Sk Life Science, INC. | $1,130.74 | 2021-2024 | Xcopri |
| Lilly USA, LLC | $945.89 | 2019-2024 | Emgality, Reyvow, Amyvid |
| Teva Pharmaceuticals USA, INC. | $752.00 | 2020-2024 | Austedo Xr, Austedo |
| Alexion Pharmaceuticals, INC. | $618.78 | 2021-2024 | Ultomiris |
| Allergan, INC. | $607.57 | 2019-2020 | |
| Amgen INC. | $550.30 | 2019-2022 | |
| Mdd US Operations, LLC | $470.59 | 2020-2024 | Gocovri, Apokyn |
| Eisai INC. | $437.39 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $402.32 | 2021-2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.